Share on StockTwits

BioScrip (NASDAQ:BIOS) Director Myron Z. Holubiak sold 5,000 shares of BioScrip stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $7.94, for a total value of $39,700.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $317,600. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of BioScrip in a research note on Monday, April 14th. They now have a $7.50 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $9.80.

Shares of BioScrip (NASDAQ:BIOS) opened at 8.14 on Friday. BioScrip has a one year low of $5.61 and a one year high of $17.62. The stock’s 50-day moving average is $7.56 and its 200-day moving average is $7.46. The company’s market cap is $557.0 million. BioScrip also saw a significant drop in short interest during the month of May. As of May 30th, there was short interest totalling 15,405,392 shares, a drop of 8.3% from the May 15th total of 16,800,846 shares. Based on an average daily volume of 1,028,079 shares, the days-to-cover ratio is currently 15.0 days. Currently, 23.4% of the company’s shares are short sold.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.10. The company had revenue of $239.60 million for the quarter, compared to the consensus estimate of $222.65 million. Analysts expect that BioScrip will post $-0.09 EPS for the current fiscal year.

BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.